Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

Lower Cabazitaxel Dose May Benefit Patients With Prostate Cancer

Reduced-dose cabazitaxel is non-inferior to the standard dose for patients with metastatic castration-resistant prostate cancer (mCRPC) who previously received docetaxel, according to results of the PROSELICA (ClinicalTrials.gov Identifier: NCT01308580) study.

Read more.

source: Cancer Therapy Advisor